article Open AccessTop 10% cited

Lower risk for cardiovascular mortality in oral 1 -hydroxy vitamin D3 users in a haemodialysis population

Nephrology Dialysis Transplantation · 2003 · Vol. 19(1) · pp. 179–184

Takahiro Shoji✉(Osaka City University)K. ShinoharaEmi KimotoM. EmotoHideki TaharaHidenori KoyamaMuneo InabaShinya FukumotoE. Ishimura(Osaka City University)Takami Miki(Osaka City University)T. Tabata(Inoue Hospital)Yoshiki Nishizawà

View via DOI Full-text PDF

Abstract

These results indicate that use of oral alfacalcidol was associated with reduced risk for cardiovascular death in this cohort of ESRD patients. The result of this observational study warrants further randomized controlled trials with 1alpha-hydroxy vitamin D3 to confirm the possibility that such medication improves survival of ESRD patients.

Vitamin D Research Studies Parathyroid Disorders and Treatments Pharmacological Effects and Toxicity StudiesAlfacalcidolMedicineInternal medicineVitamin D and neurologyProportional hazards modelCohortEnd stage renal diseasePopulationHemodialysisEndocrinology

MeSH terms

Adjuvants, ImmunologicAdministration, OralAgedCardiovascular DiseasesFemaleRenal DialysisHumansHydroxycholecalciferolsKidney Failure, ChronicMaleMiddle AgedRiskVitamin D DeficiencyCohort StudiesSurvival Analysis

Citations

352

FWCI

8.65

field-weighted impact

References

Percentile

98%

vs. same field & year

Citations per year

Cited by

Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice